# Arsenic Trioxide in Treating Patients With Relapsed or Refractory Hodgkin's Disease

> **NCT00005595** · PHASE2 · TERMINATED · sponsor: **Northwestern University** · enrollment: 2 (actual)

## Conditions studied

- Lymphoma

## Interventions

- **DRUG:** arsenic trioxide

## Key facts

- **NCT ID:** NCT00005595
- **Lead sponsor:** Northwestern University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2000-06
- **Primary completion:** 2002-04
- **Final completion:** 2002-04
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** Unable to accrue subjects in a timely fashion.
- **Last updated:** 2012-06-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00005595

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00005595, "Arsenic Trioxide in Treating Patients With Relapsed or Refractory Hodgkin's Disease". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT00005595. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*